The assessment of effect of Rosuvastatin use in venous thromboembolism

Phase 3

• Conditions: Venous thromboembolism includes deep vein thrombosis and pulmonary embolism.; venous embolism and thrombosis; Code I82

• Registration Number: IRCT20210416050990N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

patients with venous thromboembolism
In the age range of 20-75 years

Exclusion Criteria

History of inflammatory disease such as antiphospholipid syndrom
History of hematologic disorders that influence on lymphocyte, neutrophil and platetet
History of regular use of anticoagulant drugs ( valvular heart disease..) or use of anticoagulant in recent one year
Use of statins or fibrate or ezetymab
History of heart failure
history of coagulopathy
History of vein thromboembolism
History of cancer
Kidney disease under dialysis
Liver disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduce in inflammatory markers. Timepoint: At the moment of start of treatment and 3 months later. Method of measurement: Peripheral blood sample.

Secondary Outcome Measures

Name	Time	Method
Reduce of inflammation. Timepoint: 3 months later. Method of measurement: Blood sample.